As per our report, the global cancer immunotherapy market size was worth USD 88.0 Billion in 2019. This value is forecasted to grow at a CAGR of 12.52% from 2019 to 2024 and will reach USD 158.8 Billion by 2024.
Immunotherapy which is also known as biologic therapy, can be performed in two ways. That is by stimulating one’s immune system to fight against the disease by attacking defected cancer cells, and by giving constituents of the immune system from outside such as synthetic proteins into the body to fight against the disease. It is performed to treat cancer patients from long, even when doctors did not thoroughly understand the immune system. Immunotherapy is a treatment option that uses certain parts of an immune system to fight against various diseases such as cancer.
Cancer immunotherapy is a type of therapy used to treat various cancer diseases that involves stimulation and suppression of the immune system. It is made by white blood cells, organs and tissue of the lymphatic system. There are several companies which are investing massive amounts for the treatment of cancer. Currently, U.S. food and administration has approved 32 various immunotherapies to treat for 20 cancer types including cell-based immunotherapies, immunomodulators, BCG vaccines, targeted therapies and oncotic viruses.
MARKET DRIVERS
Growing occurrence of cancer, rising number of R & D and technological developments in treatment options are majorly fuelling the global cancer immunotherapy market.
Cancer has now become one of a leading cause of death throughout the world. According to the statistics published by the World Health Organization (WHO), an estimated of 9.6 million were died of cancer in the year 2018 and also found tobacco as the leading risk factor for cancer and recorded 22% of responsibility in cancer deaths happened in 2018. The noticed increasing prevalence in cancer is estimated to favour the growth of the global cancer immunotherapy market.
Additionally, the global cancer immunotherapy is fuelled by the high efficacy of immunotherapy compared to other treatments, fewer side effects associated with cancer immunotherapy, reduced the chance of recurrence of cancer. Some of the other notable drivers expanding the market size are technological advances in clinical therapies, an increase in the number of R&Ds for cancer treatment, and the specificity and efficacy of cancer immunotherapy for the treatment of a wide range of cancers.
Rising adoption of advanced therapeutics for cancer and growing implementation in the healthcare sector to treat cancer diseases is also supporting the growth of the global cancer immunotherapy market. Also, public organizations are focusing on investment in Research and development activities to develop new cancer immunotherapy. Development of CAR –T cell therapy is also propelling market growth.
MARKET RESTRAINTS
The primary factor restraining the growth of the market is various cancer like Melanoma shows resistance towards chemotherapy and radiation therapies, Cost of cancer therapies, limited information on cancer immunobiology. Furthermore, the high competition in the product development cycle is restraining the demand of the market. Depending upon the cancer types and cancer patients, it is complicated to develop a new drug with high quality which is also a factor impeding the demand of the market. Also, lack of skill professional and lack of awareness among the people hamper the market growth.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Type of Therapies, Area of therapy and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
This market research report on global cancer immunotherapy market has been segmented and sub-segmented based on the type of therapies, area of therapy and region.
Cancer Immunotherapy Market – By Type of Therapies
Based on the type of therapies, the monoclonal antibodies have the largest market share and are projected to grow throughout the forecast period with the highest growth rate. The rise in the use of monoclonal antibodies to treat a wide variety of cancers like breast cancer, lymphoma, lung cancer, brain cancer, cervical cancer, and others is the primary trend driving the market. Because of the high drug specificity towards cancer cells, this is mainly attributed to the technological superiority of this approach. These drugs are designed to identify and create a targeted immune response to cancer cells based on their proteins on the cell surface and to forgo normal cells.
Monoclonal antibody segment has the most significant growth in the previous year due to high investment in R&D. Some monoclonal antibodies used for the targeted treatment of cancer. There are various types of monoclonal antibodies such as naked, conjugated and bispecific monoclonal antibodies. Now AbbVie product Adalimumab monoclonal antibody was the highest selling product in 2019.
Cancer Immunotherapy Market – By Area of Therapy
Based on therapy, there is an increasing use of cancer immunotherapy for melanoma therapy. Melanoma segment growth can be directly linked to new product development, a large number of FDA approvals, and extensive research and development in this area. Recently, the U.S. FDA has approved three melanoma treatment checkpoint inhibitors, three cytokine therapies, and one oncolytic virus therapy.
Lung cancers had the most substantial market revenue in 2019. In 2020, the U.S. food and drug administration has approved Tabrecta (Capmatinib) for the treatment of non-small cell lung cancer. Melanoma is the fastest-growing segment due to advanced new development in the cancer immunotherapy market.
Cancer Immunotherapy Market – By Region
Last Year, North America held the largest share of the revenue in the global cancer immunotherapy market. Increasing disease incidence, increasing accessibility to modern therapy, combined with a growing geriatric population, lead to regional market development. The North American market is further growing due to highest cancer caused population, aged population, and modern lifestyle in the region. There is a noticeable increase in the biotechnology companies in the U.S. as compared to the previous year, which is driving the cancer immunotherapy market in North America.
Europe region has significant growth in the cancer immunotherapy market due to advanced technology and various clinical trials performed in Europe.
Throughout the forecast period, Asia Pacific is expected to experience the fastest growth. Chinese and Japan are introducing new and sophisticated immunotherapy medications. These countries have many current clinical trials for new drug molecules and alternative treatments as well as FDA approvals. Approval of new treatment drugs in China and Japan is improving the tumour treatment acceptance of immunotherapy.
Recently, food and drug administration approved new technologies and implementation in China and Japan for the treatment of small-cell lung cancer. India is driving the cancer immunotherapy market due to the vast population and genetic variation. The recent FDA approved, and new drug introduction in the market is propelling the market growth.
TOP COMPANIES IN THE MARKET
Companies leading the global cancer immunotherapy market profiled in the report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co, Celgene Corp and Immunomedics.
RECENT MARKET DEVELOPMENTS
In 2019, Roche Holding AG received approval to launch its atezolizumab new cancer immunotherapy in India. It is beneficial to treat small cell lung cancer patients with chemotherapy. Also, the company wants to expand its developed market in India for the treatment of cancer disorders.
In 2019, Merck introduced new cancer immunotherapy, Keytruda with Pfizer Inlyta to minimize the risk of kidney cancer disease. The drug will give a high response rate and improved progression as compared to treatment with chemotherapy.
In March 2020, Forty-seven was acquired by Gilead Life sciences. This acquisition has helped the Gilead to expend their global cancer immunotherapy treatment for various diseases. Forty-seven has lead product magrolimab, and it is a monoclonal antibody used for the treatment of acute myeloid leukaemia and B-cell lymphoma.
In October 2015, the FDA approved the first oncolytic virus therapy known as Talimogene laherparepvec (T-VEC or Imlygic). The vaccine is used to treat metastatic melanoma that cannot be eliminated by surgery.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Breast
5.1.3 Lung
5.1.4 Melanoma
5.1.5 Colorectal
5.1.6 Head & Neck
5.1.7 Prostate
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Application
5.1.10 Market Attractiveness Analysis, By Application
5.1.11 Market Share Analysis, By Application
5.2 Product Type
5.2.1 Introduction
5.2.2 Monoclonal Antibodies
5.2.3 Checkpoint inhibitors/immune modulators
5.2.4 Therapeutic cancer vaccines
5.2.5 Oncolytic virus immunotherapy
5.2.6 Cytokines
5.2.7 Adoptive T cell transfer
5.2.8 Adjuvant Immunotherapy
5.2.9 Interferons
5.2.10 Interleukins
5.2.11 BCG
5.2.12 Others
5.2.13 Y-o-Y Growth Analysis, By Product Type
5.2.14 Market Attractiveness Analysis, By Product Type
5.2.15 Market Share Analysis, By Product Type
5.3 Mode of Administration
5.3.1 Introduction
5.3.2 Intravenous
5.3.3 Oral
5.3.4 Topical
5.3.5 Intra Vesical
5.3.6 Y-o-Y Growth Analysis, By Mode of Administration
5.3.7 Market Attractiveness Analysis, By Mode of Administration
5.3.8 Market Share Analysis, By Mode of Administration
5.3 End users
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Y-o-Y Growth Analysis, By End users
5.3.5 Market Attractiveness Analysis, By End users
5.3.6 Market Share Analysis, By End users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product Type
6.1.3.4 By Mode of Administration
6.1.3.5 By End users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Product Type
6.1.4.4 By Mode of Administration
6.1.4.5 By End users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Product Type
6.1.5.4 By Mode of Administration
6.1.5.6 By End users
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen
8.3 Viralytics
8.4 Novartis Pharmaceuticals Corporation
8.5 Pfizer
8.6 GlaxoSmithKline Pharmaceuticals Limited
8.7 AstraZeneca plc
8.8 Medivation
8.9 Advaxis
8.10 Bristol-Myers Squibb
8.11 Merck & Co. and Celgene Corp
8.12 Immunomedics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
